Rylaze is a Intramuscular Injection in the Human Prescription Drug category. It is labeled and distributed by Jazz Pharmaceuticals, Inc.. The primary component is Asparaginase.
Product ID | 68727-900_19a01d9d-35ce-49dc-a2c9-958a1db5f895 |
NDC | 68727-900 |
Product Type | Human Prescription Drug |
Proprietary Name | Rylaze |
Generic Name | Asparaginase Erwinia Chrysanthemi (recombinant)-rywn |
Dosage Form | Injection |
Route of Administration | INTRAMUSCULAR |
Marketing Start Date | 2021-06-30 |
Marketing Category | BLA / |
Application Number | BLA761179 |
Labeler Name | Jazz Pharmaceuticals, Inc. |
Substance Name | ASPARAGINASE |
Active Ingredient Strength | 20 mg/mL |
Pharm Classes | Asparaginase [CS], Asparagine-specific Enzyme [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2021-06-30 |
NDC Exclude Flag | N |
Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
RYLAZE 88789656 not registered Live/Pending |
Jazz Pharmaceuticals Ireland Limited 2020-02-07 |